ALTERNATIVE FINANCING FORMS
FOR ENTREPRENEURS AND INVESTORS
News

DLA Piper advises Evers sale to Bright Future Pharma Labs

Cate­gory: Deals
22. Febru­ary 2018

Pinnen­berg — The phar­maceu­ti­cal factory Evers GmbH & Co KG sells to the Chinese company Bright Future Phar­maceu­ti­cal Labo­ra­to­ries Ltd. The company produ­ces mainly natu­ral medi­ci­nes for the urology and gastro­en­te­ro­logy sector, which are sold inter­na­tio­nally and very stron­gly on the Asian market, espe­ci­ally in Japan and China. The parties have agreed not to disc­lose the purchase price.

The family busi­ness Phar­ma­zeu­ti­sche Fabrik Evers GmbH & Co KG was foun­ded in 1933. Head­quar­te­red in Pinne­berg, near Hamburg, Germany, the company focu­ses on a selec­ted range of natu­ral medi­ci­nes for the urology and gastro­en­te­ro­logy sectors and acts as a licen­sor in seve­ral count­ries. The Evipro­stat S, Evipro­stat N and Gallith brands are among the estab­lished products in this field.

Estab­lished in 1993, Bright Future Phar­maceu­ti­cal Labo­ra­to­ries Ltd is the largest GMP (Good Manu­fac­tu­ring Prac­tice) certi­fied phar­maceu­ti­cal manu­fac­tu­rer in Hong Kong. The company, with more than 7,000 employees, provi­des people with access to medi­ci­nes at afforda­ble prices and is parti­cu­larly active in key growth markets such as Hong Kong, main­land China, North America, Africa, Southe­ast Asia and Europe.

Advi­sors to Evers GmbH & Co KG: DLA Piper
The tran­sac­tion once again under­lines the exten­sive expe­ri­ence of the DLA Piper German China Desk, this time on the German seller side.

The core team of DLA Piper under the leader­ship of part­ner Dr. Nils Krause (photo ) contin­ued to consist of senior asso­ciate Dr. Jan-Phil­ipp Meier and asso­cia­tes Dr. Jasper von Georg and Ronja Hecker (all Corpo­rate, Hamburg). In addi­tion, Part­ner Guido Kleve, Coun­sel Dr. Thilo Streit (both Liti­ga­tion and Regu­la­tory, Colo­gne) and Chris­tian Lonquich (Real Estate, Frank­furt) as well as Tran­sac­tion Lawyer Hui Hao (Corpo­rate, Hamburg) were part of the team.

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at] fyb.de